Comparative Pharmacology
Head-to-head clinical analysis: AVANAFIL versus STENDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVANAFIL versus STENDRA.
AVANAFIL vs STENDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing nitric oxide-mediated relaxation of smooth muscle in the corpus cavernosum, increasing cGMP levels, and promoting penile erection.
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation in corpus cavernosum, leading to smooth muscle relaxation and increased penile blood flow.
100 mg orally once daily, taken 30-60 minutes before sexual activity. Maximum dosing frequency: once daily.
50 mg orally once daily as needed, 1 hour before sexual activity. Maximum dose 100 mg. Maximum frequency once daily.
None Documented
None Documented
Clinical Note
moderateAvanafil + Torasemide
"Avanafil may increase the antihypertensive activities of Torasemide."
Clinical Note
moderateAvanafil + Travoprost
"Avanafil may increase the antihypertensive activities of Travoprost."
Clinical Note
moderateAvanafil + Unoprostone
"Avanafil may increase the antihypertensive activities of Unoprostone."
Clinical Note
moderateAvanafil + Hydrochlorothiazide
"Avanafil may increase the antihypertensive activities of Hydrochlorothiazide."
Terminal elimination half-life approximately 6-8 hours. Clinical context: Supports once-daily dosing; steady-state reached within 5 days with no accumulation at FDA-approved dose.
Terminal elimination half-life is approximately 4 hours in healthy subjects; may be prolonged in hepatic impairment (Child-Pugh B: up to 6 hours) or with concomitant CYP3A4 inhibitors.
Primarily hepatic metabolism via CYP3A4 and CYP2C9, with metabolites excreted in feces (approximately 82-90%) and urine (approximately 6-8% as unchanged drug and minor metabolites).
Fecal (approximately 63%) and renal (approximately 21%) as metabolites; less than 2% excreted unchanged in urine.
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor